Latest News and Press Releases

NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from...

Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust and sustained biomarker improvement across...

NEW YORK and CLEVELAND, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies...

ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...

--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...

NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...

NEW YORK and CLEVELAND, June 02, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...

NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...

NEW YORK and CLEVELAND, May 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...